Used in the development of therapies for lowering LDL cholesterol by inhibiting PCSK9, a protein that reduces the liver's ability to remove bad cholesterol from the bloodstream. This antibody serves as a reference in biosimilar development, quality control, and analytical testing of PCSK9 inhibitors. It enables accurate comparison of new anti-PCSK9 drugs to established ones, ensuring consistency, efficacy, and safety in pharmaceutical manufacturing. Also utilized in research settings to study lipid metabolism and cardiovascular disease mechanisms.